Nisa Investment Advisors
OBIO icon

Nisa Investment Advisors’s Orchestra BioMed OBIO Stock Holding History

Nisa Investment Advisors’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-241
Closed -$646 – 3057
2025
Q2 		$646 Sell
241
-564
-70% -$1.65K ﹤0.01% 2830
2025
Q1 		$3.44K Buy
805
+733
+1,018% +$3.64K ﹤0.01% 2334
2024
Q4 		$288 Buy
72
+2
+3% +$11 ﹤0.01% 2902
2024
Q3 		$360 Buy
70
+39
+126% +$255 ﹤0.01% 2776
2024
Q2 		$253 Buy
31
+27
+675% +$156 ﹤0.01% 2788
2024
Q1 		$21 Buy
+4
New +$27 ﹤0.01% 2778
2023
Q4 		– Sell
-22
Closed -$192 – 2713
2023
Q3 		$192 Buy
+22
New +$148 ﹤0.01% 2672

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nisa Investment Advisors's OBIO Position: Q3 2025 in Review

Nisa Investment Advisors sold out of Orchestra BioMed (OBIO) in Q3 2025, closing a stake of 241 shares — an estimated $646 sold.

Nisa Investment Advisors first reported a position in OBIO in Q3 2023 and held it in 7 quarters. The position peaked at $3.44K in Q1 2025. 52 funds tracked by Wall St. Rank hold OBIO as of Q3 2025.

  • Nisa Investment Advisors reported no remaining Orchestra BioMed position as of Q3 2025 after selling out during the quarter.
  • Nisa Investment Advisors sold 241 Orchestra BioMed shares in Q3 2025, an estimated $646.
  • Nisa Investment Advisors first reported a position in Orchestra BioMed in Q3 2023 and held it in 7 quarters.
  • Nisa Investment Advisors's Orchestra BioMed position peaked at $3.44K in Q1 2025.
  • 52 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2025.

Based on Nisa Investment Advisors's 13F filing for Q3 2025, filed 23 Oct 2025.